Ginkgo Bioworks (DNA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$132.4M

Revenue (quarter)

$20.2M

Revenue growth (year over year)

−48.49%

Gross profit (trailing twelve months)

$90.1M

Gross margin

68.04%

Net income (trailing twelve months)

−$290.8M

Net income (quarter)

−$46.7M

Net income growth (year over year)

+22.54%

Net margin

−219.60%

Return on equity

−56.29%

EPS (trailing twelve months)

−$5.00

Book value per share

$6.60

P/E (trailing twelve months)

—

Price to book

1.88

Debt to assets

57.55%

Payout ratio

—

Dividend yield

—

Company profile

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

• Is Ginkgo Bioworks (DNA) profitable?

  No. Ginkgo Bioworks reported a net loss of $290.8M over the trailing twelve months.

• How much revenue does Ginkgo Bioworks (DNA) make?

  Ginkgo Bioworks generated $132.4M in revenue over the trailing twelve months, down 48.49% year over year.

• How do I buy stock in Ginkgo Bioworks (DNA)?

  DNA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.